NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

In late 2013 the Company began a pursuit to change the trial, to "enhance it". The process took well into the next year. Shareholders were unaware that the trial was on any clinical halt. In August 2014, they issued a press release (below) that the changes were made to the statistical analysis to account for a "low white blood cell" count that patients experienced after chemotherapy. But, they were still working on European approvals. THIS patent has very much to do with being able to produce a higher potency leukapheresis draw. The VACCINE they use in the trial is the same vaccine they used in the compassionate use arm program. The only way to go from being able to MANUFACTURE a significant supply from 3 to 17 is if this US patent is in use. It has an equivalent patent counterpart in Europe, which as I remember was issued sometime in 2014. And what your unique experience is telling me is that this PATENT IS NOW in use for DCVax-L. Thank you for sharing it.

This tangential flow patent is the difference in the number of injections. Review the patent for yourself.

http://patents.justia.com/patent/8518636

http://www.nasdaq.com/markets/spos/filing.ashx?filingid=9193123

And getting this patent approved to be used in the Phase III trial, in the DCVax-L product, was likely the low WBC count they referenced in their 2014 press release. It is a patent for the "next generation process for manufacturing higher quality and higher reliability dendritic cells".

An individual patient's case offers a perspective but it does not give insight to everything. Trust me I know firsthand, as my nephew's DCVax-L's clinical experience does not me an expert either. However, I have been following this trial a lot longer than most so I do know what I'm talking about when I refer to things. And I have no issue admitting to times when I interpret something wrong. Only here I do not think that is the case. So what I'm trying to communicate to you is that I believe they were able to get this PATENT "enhancement" for use in use in this Phase III trial for DCVax-L, and that is a wonderful thing!

http://www.nwbio.com/nw-bio-obtains-approvals-for-enhancements-of-phase-iii-trial-of-dcvax-l-for-gbm-brain-cancer/